货号 (SKU)

包装规格

是否现货

价格

数量

Ab176615-100μg

100μg

现货

Ab176615-1mg

1mg

现货

Ab176615-5mg

5mg

现货

Ab176615-10mg

10mg

期货

基本信息

产品名称	Ravulizumab (anti-Complement C5), 补体 C5 抑制剂
别名	雷夫利珠单抗 \| 雷维珠单抗(抗补体 C5)
英文别名	Anaphylatoxin C5a analog antibody \| C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 antibody \| C5 antibody \| C5a anaphylatoxin antibody \| C5a antibody \| C5b antibody \| CO5_HUMAN antibody \| Complement C5 alpha'' chain antibody \| Complemen
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	C5
种属反应性	人(Human),小鼠(Mouse),恒河猴(Rhesus monkey),食蟹猴(Cynomolgus monkey)
偶联	Unconjugated
作用类型	抑制剂
作用机制	补体 C5 抑制剂

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG2
轻链亚型	kappa
SDS-PAGE	145.80 kDa
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1803171-55-2
分子类型	抗体

关联靶点（人）

C5 Tclin 补体 C5(Complement C5) (0 活性数据)

点击查看靶蛋白信息： C5

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

SEC: Ravulizumab (anti-Complement C5) (Ab176615)

Ravulizumab (anti-Complement C5) (Ab176615) - SEC
The purity of Ravulizumab (anti-Complement C5) (Ab176615) is more than 95% verified by HPLC.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到7个结果

批号(Lot Number)	证书类型	货号
ZJ23F1202177	分析证书	Ab176615
ZJ23F1202178	分析证书	Ab176615
ZJ24F1214702	分析证书	Ab176615
ZJ24F1214701	分析证书	Ab176615
ZJ24F0809460	分析证书	Ab176615
ZJ24F0809459	分析证书	Ab176615
ZJ24F0809458	分析证书	Ab176615

可替换产品

引用文献

1. Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T et al.. (2014) Genetic variants in C5 and poor response to eculizumab.. N Engl J Med, 370 (7): (632-9). [PMID:24521109]
2. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.. Nat Biotechnol, 25 (11): (1256-64). [PMID:17989688]
3. Fernandez, H N HN and Hugli, T E TE.. (1978) Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a.. The Journal of biological chemistry, (10): [PMID:690134]
4. Haviland, D L DL, Haviland, J C JC, Fleischer, D T DT, Hunt, A A and Wetsel, R A RA.. (1991) Complete cDNA sequence of human complement pro-C5. Evidence of truncated transcripts derived from a single copy gene.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:1984448]
5. Bohnsack, J F JF, Mollison, K W KW, Buko, A M AM, Ashworth, J C JC and Hill, H R HR.. (1991) Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus.. The Biochemical journal, (1): [PMID:1996961]
6. Lundwall, A B AB and 7 more authors.. (1985) Isolation and sequence analysis of a cDNA clone encoding the fifth complement component.. The Journal of biological chemistry, (25): [PMID:2579066]
7. Zuiderweg, E R ER and Fesik, S W SW.. (1989) Heteronuclear three-dimensional NMR spectroscopy of the inflammatory protein C5a.. Biochemistry, (21): [PMID:2730871]
8. Zuiderweg, E R ER, Nettesheim, D G DG, Mollison, K W KW and Carter, G W GW.. (1989) Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data.. Biochemistry, (10): [PMID:2784981]
9. Wetsel, R A RA and 5 more authors.. (1988) Molecular analysis of human complement component C5: localization of the structural gene to chromosome 9.. Biochemistry, (8): [PMID:3365401]
10. Zuiderweg, E R ER, Mollison, K W KW, Henkin, J J and Carter, G W GW.. (1988) Sequence-specific assignments in the 1H NMR spectrum of the human inflammatory protein C5a.. Biochemistry, (17): [PMID:3408713]
11. Wang, X X and 7 more authors.. (1995) Inherited human complement C5 deficiency. Nonsense mutations in exons 1 (Gln1 to Stop) and 36 (Arg1458 to Stop) and compound heterozygosity in three African-American families.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:7730648]
12. Zhang, X X, Boyar, W W, Galakatos, N N and Gonnella, N C NC.. (1997) Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding.. Protein science : a publication of the Protein Society, [PMID:9007977]
13. Zhang, X X, Boyar, W W, Toth, M J MJ, Wennogle, L L and Gonnella, N C NC.. (1997) Structural definition of the C5a C terminus by two-dimensional nuclear magnetic resonance spectroscopy.. Proteins, [PMID:9188742]
14. Chen, Z Z and 5 more authors.. (1998) Residues 21-30 within the extracellular N-terminal region of the C5a receptor represent a binding domain for the C5a anaphylatoxin.. The Journal of biological chemistry, (24): [PMID:9553099]
15. Delgado-Cerviño, Eva E, Fontán, Gumersindo G and López-Trascasa, Margarita M.. (2005) C5 complement deficiency in a Spanish family. Molecular characterization of the double mutation responsible for the defect.. Molecular immunology, [PMID:15488949]
16. Bramham, Janice J and 5 more authors.. (2005) Functional insights from the structure of the multifunctional C345C domain of C5 of complement.. The Journal of biological chemistry, (18): [PMID:15598652]
17. Pfarr, Nicole N and 12 more authors.. (2005) Linking C5 deficiency to an exonic splicing enhancer mutation.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:15778377]
18. Hillebrandt, Sonja S and 13 more authors.. (2005) Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans.. Nature genetics, [PMID:15995705]
19. Singer, Andrew L AL and 9 more authors.. (2009) Successful liver transplantation for Budd-Chiari syndrome in a patient with paroxysmal nocturnal hemoglobinuria treated with the anti-complement antibody eculizumab.. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, [PMID:19399743]
20. Kelly, Richard; Richards, Stephen; Hillmen, Peter and Hill, Anita.. (2009) The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab.. Therapeutics and clinical risk management, [PMID:20011245]
21. Laursen, Nick S NS and 5 more authors.. (2011) Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex.. The EMBO journal, (2): [PMID:21217642]
22. Jore, Matthijs M and 7 more authors.. (2016) Structural basis for therapeutic inhibition of complement C5.. Nature structural & molecular biology, [PMID:27018802]
23. Reichhardt, Martin P and 8 more authors.. (2020) An inhibitor of complement C5 provides structural insights into activation.. Proceedings of the National Academy of Sciences of the United States of America, (7): [PMID:31871188]
24. Chen, X X, Ji, Z L ZL and Chen, Y Z YZ.. (2002) TTD: Therapeutic Target Database.. Nucleic acids research, (1): [PMID:11752352]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Ravulizumab (anti-Complement C5), 补体 C5 抑制剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

可替换产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

Ravulizumab (anti-Complement C5), 补体 C5 抑制剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器